Zomig, Zolmitriptan Newswire

Zomig, Zolmitriptan Newswire

Comprehensive Real-Time News Feed for Zomig, Zolmitriptan (generic).

Results 1 - 11 of 11 in Zomig, Zolmitriptan (generic)

  1. Zosano Pharma: There Is More Upside Despite Recent Run-UpRead the original story w/Photo

    Tuesday Feb 28 | Seeking Alpha

    The company's stock has been on a tear for the past week after announcing successful phase 3 results of M207 in acute migraine. Zosano Pharma is an emerging lifesciences company that is developing novel treatments for diseases using its proprietary transdermal delivery platform.

    Comment?

  2. Zosano Pharma Announces Last Subject Treated in its Migraine Pivotal TrialRead the original story

    Jan 5, 2017 | World News Report

    "Having reached this milestone for the Zotrip study reinforces our expectation that top-line data will be reported in the first quarter of 2017 as planned," commented Konstantinos Alataris, PhD, President and Chief Executive Officer of Zosano Pharma. "On behalf of the entire management team, I would like to extend our sincere appreciation to Zotrip's investigators and study participants for their shared commitment to finding improved treatment options for those suffering with migraine."

    Comment?

  3. Read the original story w/Photo

    Dec 13, 2016 | Customize.org

    A dangerous drug interaction could dangerous or life-threatening side effects. Ask your doctor before taking Celexa with a sleeping pill, narcotic pain medicine, muscle relaxer, Celexas or medicine for anxiety, depression, or seizures.

    Comment?

  4. Now Available: Suven Life Sciences Ltd. (SUVEN) - Financial and Strategic SWOT Analysis ReviewRead the original story w/Photo

    Dec 2, 2016 | PR-inside.com

    Summary Suven Life Sciences Ltd is a biopharmaceutical company that designs, manufactures and supplies API's, advanced intermediates, and fine chemicals. The company's API's include aripiprazole, calcium acetate, divalproex sodium, entacapone, fenoprofen calcium, gabapentin, glycopyrrolate, iron sucrose complex for injection, losartan potassium, malathion lotion, nitazoxanide, pamabrom, sodium ferric gluconate for injection, verapamil hydrochoride and zolmitriptan.

    Comment?

  5. Zosano Announces Completion Of Enrollment In Pivotal Efficacy Trial For M207 For Acute MigraineRead the original story

    Nov 7, 2016 | BioSpace

    Zosano Pharma Corporation , an emerging CNS company focused on providing rapid symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced completion of enrollment in its registration-enabling, pivotal efficacy trial , of M207 for the treatment of acute migraine. "The completion of enrollment in the Zotrip study is a major milestone for the Company and bolsters our confidence in the previously announced availability of trial data in the first quarter of 2017," commented Konstantinos Alataris, PhD, President and Chief Executive Officer of Zosano Pharma.

    Comment?

  6. The People's Pharmacy: Oxygen saves man from 'suicide headaches'Read the original story w/Photo

    Nov 5, 2016 | HeraldSun.com

    Q. I am 30 years old and have suffered for nine years with cluster headaches. I would get them every day for a month straight.

    Comment?

  7. First Subject Treated In Zosano's Pivotal Efficacy Trial For M207 Patch For Acute MigraineRead the original story

    Jul 24, 2016 | BioSpace

    Zosano Pharma Corporation , an emerging CNS company focusing on providing rapid symptom relief to patients using the Company's proprietary transdermal delivery system, today announced the dosing of its first subject in its registration-enabling pivotal efficacy trial , of its M207 patch, formerly known as ZP-Triptan, for the treatment of acute migraine. "I'm extremely pleased to announce our first subject treated in the Zotrip trial.

    Comment?

  8. Zosano Pharma's pivotal study of ZP-Triptan patch for migraine underwayRead the original story w/Photo

    Jun 17, 2016 | Seeking Alpha

    The first patient has been enrolled in Zosano Pharma's Phase 2/3 clinical trial assessing its ZP-Triptan patch for the treatment of acute migraine. The 360-subject, randomized, placebo-controlled, parallel-group study will compare three doses of ZP-Triptan to placebo for the treatment of a single migraine attack.

    Comment?

  9. Acorda Presents Phase I Data On CVT-427 For Acute Treatment Of Migraine AtRead the original story

    Jun 8, 2016 | BioSpace

    Acorda Therapeutics, Inc. today announced pharmacokinetic data from a Phase 1 study of CVT-427, an inhaled formulation of zolmitriptan, resulting in increased bioavailability and faster absorption compared to oral and nasal administration of the same active ingredient in healthy adults. The data on CVT-427, an investigational agent under development for the acute treatment of migraines, will be presented on June 10th, 2016, at the 58th Annual Scientific Meeting of the American Headache Society, in San Diego, CA.

    Comment?

  10. FDA approves Aurobindo's generic ZomigRead the original story w/Photo

    May 25, 2016 | Drug Store News

    The Food and Drug Administration has approved Aurobindo Pharma's generic Zomig tablets, the company announced Wednesday. The drug is indicated for acute treatment of migraine with or without aura in adults.

    Comment?

  11. Ajanta Pharma gets USFDA nod for migraine drugRead the original story w/Photo

    May 24, 2016 | DNA India

    Ajanta Pharma has received the final approval for its generic version of acute migraine pain relief drug Zolmitriptan tablets from the US health regulator. "The company received the final approval for Zolmitriptan tablets from the US Food and Drug Administration .

    Comment?